
    
      Study treatment: TCP + ATRA + AraC Four dose levels of TCP (20 mg, 40 mg, 60 mg, 80 mg on
      days 1-28) will be examined in combination with fixed dose ATRA (45 mg/m2 on days 10-28) and
      fixed-dose AraC (40 mg on days 1-10) in the first cycle.

      In further cycles patients will be treated in the same manner, except for ATRA which will be
      administered continuously with a nine-day interruption at the beginning of every fourth
      cycle.

      Follow-up per patient: Until twelve months after registration of the last patient.

      Duration of intervention per patient: Until relapse/progression, unacceptable toxicity or
      until twelve months after registration of the last patient, whatever occurs first
    
  